↓ Skip to main content

The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis

Overview of attention for article published in BMC Cancer, July 2006
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (75th percentile)
  • High Attention Score compared to outputs of the same age and source (82nd percentile)

Mentioned by

peer_reviews
1 peer review site
wikipedia
1 Wikipedia page

Citations

dimensions_citation
53 Dimensions

Readers on

mendeley
23 Mendeley
connotea
1 Connotea
Title
The role of sialomucin CD164 (MGC-24v or endolyn) in prostate cancer metastasis
Published in
BMC Cancer, July 2006
DOI 10.1186/1471-2407-6-195
Pubmed ID
Authors

AM Havens, Y Jung, YX Sun, J Wang, RB Shah, HJ Bühring, KJ Pienta, RS Taichman

Abstract

The chemokine stromal derived factor-1 (SDF-1 or CXCL12) and its receptor CXCR4 have been demonstrated to be crucial for the homing of stem cells and prostate cancers to the marrow. While screening prostate cancers for CXCL12-responsive adhesion molecules, we identified CD164 (MGC-24) as a potential regulator of homing. CD164 is known to function as a receptor that regulates stem cell localization to the bone marrow.

Mendeley readers

The data shown below were compiled from readership statistics for 23 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 1 4%
Germany 1 4%
Italy 1 4%
Unknown 20 87%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 7 30%
Professor 5 22%
Student > Master 4 17%
Researcher 2 9%
Lecturer > Senior Lecturer 1 4%
Other 3 13%
Unknown 1 4%
Readers by discipline Count As %
Agricultural and Biological Sciences 10 43%
Medicine and Dentistry 6 26%
Biochemistry, Genetics and Molecular Biology 2 9%
Social Sciences 1 4%
Immunology and Microbiology 1 4%
Other 2 9%
Unknown 1 4%

Attention Score in Context

This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 04 June 2017.
All research outputs
#3,122,030
of 12,372,945 outputs
Outputs from BMC Cancer
#768
of 4,558 outputs
Outputs of similar age
#47,382
of 202,214 outputs
Outputs of similar age from BMC Cancer
#7
of 41 outputs
Altmetric has tracked 12,372,945 research outputs across all sources so far. This one has received more attention than most of these and is in the 73rd percentile.
So far Altmetric has tracked 4,558 research outputs from this source. They receive a mean Attention Score of 3.9. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 202,214 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 41 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 82% of its contemporaries.